Abstract
A phase III randomized trial was conducted in patients with metastatic NSCLC, to determine if, in association with mitomycin (6 mg m–2) and ifosfamide (3 g m–2), the combination of moderate dosages of cisplatin (60 mg m–2) and carboplatin (200 mg m–2) – CarboMIP regimen – improved survival in comparison with cisplatin (50 mg m–2) alone – MIP regimen. A total of 305 patients with no prior chemotherapy were randomized, including 297 patients assessable for survival (147 in the MIP arm and 150 in the CarboMIP arm) and 268 patients assessable for response to chemotherapy. All but eight (with malignant pleural effusion) had stage IV disease. There was a 27% (95% CI, 19–34) objective response (OR) rate to MIP (25% of the eligible patients) and a 33% (95% CI, 24–41) OR rate to CarboMIP (29% of the eligible patients). This difference was not statistically significant (P = 0.34). Duration of response was not significantly different between both arms. There was also no difference (P = 0.67) in survival: median survival times were 28 weeks (95% Cl, 24–32) for MIP and 32 weeks (95% Cl, 26–35) for CarboMIP, with respectively 1-year survival rates of 24% and 23% and 2-year survival rates of 5% and 2%. The main toxicities consisted in emesis, alopecia, leucopenia and thrombocytopenia, that were, except alopecia, significantly more severe in the CarboMIP arm. Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone. The results support the use of a moderate dose (50 mg m–2) of cisplatin in combination with ifosfamide and mitomycin for the chemotherapy of this disease. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R and Glick J (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage iv non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602–1613
Borges M, Sculier JP, Paesmans M, Richez M, Bureau G, Dabouis G, Lecomte J, Michel J, Van Cutsem O, Schmerber J, Giner V, Berchier MC, Sergysels R, Mommen P and Klastersky J (1996) Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC). Lung Cancer 16: 21–33
Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Constanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F and Tonato M (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522–3530
Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Constanzo F, Buzzi F, Fornari G, Santi E, Ballatori E, Santucci C and Davis S (1990) A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 26: 52–56
Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J and Souhami RL (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188–3194
Cullen MH, Joshi R, Chetiyawardana AD and Woodroffe CM (1988) Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 58: 359–361
Depierre A, Chastang CI, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Salal-Celigny P, Badri N and Benseval M (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: a randomized trial. Ann Oncol 5: 37–42
Donnadieu N, Paesmans M and Sculier JP (1991) Chimiothérapie des cancers bronchiques non à petites cellules. Méta-analyse de la littérature en fonction de l’extension de la maladie. Rev Mal Resp 8: 197–204
Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn Drasga R, Songer J, Fisher W, Stephens D and Hui S (1986) Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatine plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4: 1037–1043
Elliott JA, Ahmedzai S, Hole D, Dorward AJ, Stevenson RD, Kaye SB, Banham SW, Stack BHR and Calman KC (1984) Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 20: 1025–1032
Fuks JZ, Aisner J, Van Echo DA, Schipper H, Levitt M, Ostrow S and Wiernik Ph (1983) Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16–213) with or without cisplatinum in non-small cell lung cancer. J Clin Oncol 1: 295–301
Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M and Kusunoki Y (1991) A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9: 606–613
Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB and Balcerzak P (1993) Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873–878
Giaccone G, Splinter TA and Debruyne C (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133–2141
Gralla RJ, Casper ES, Kelsen DP, Braun DP, Dukeman ME, Martini N, Young CW and Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414–420
Grilli R, Andrew D, Oxman AD and Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol 11: 1866–1872
Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N and Rapp E (1990) Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non small-cell lung cancer. J Clin Oncol 8: 1301–1309
Kawahara M, Furuse K, Kodama N, Yamamoto M, Kubota K, Takada M, Negoro S, Kusunoki Y, Matui K and Takifuji N (1991) A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 68: 714–719
Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, Thiriaux J, Lecomte J, Cordier R, Dabouis G, Brohée D, Thémelin L and Mommen P for the Lung Cancer Working Party (1989) Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 7: 1087–1092
Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P and Paesmans M (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8: 1556–1562
Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P, Bonduelle Y, Mairesse M, Michiels T, Thiriaux J, Mommen P and Dalesio O the EORTC Lung Cancer Working Party (1986) A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 4: 1780–1786
Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Rivière A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaiolo A, Benseval M, Besson F, Martinez A, Berthaud P and Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360–367
Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R and Greco FA (1990) Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer Study Group trial. J Clin Oncol 8: 886–891
Marino P, Pampallona S, Preatoni A, Cantoni A and Invernizzi F (1994) Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 106: 861–865
Meert AP, Berghmans T, Branle F, Lemaitre F, Mascaux C, Rubesova E, Vermylen P, Paesmans M and Sculier JP (1999) Phase II and III studies with new drugs for non-small cell lung cancer. A systematic review of the literature with a methodology quality assessment. Anticancer Res 19: 4379–4390
Mylonakis N, Tsavaris N, Bacoyiannis C, Karvounis N, Kakolyris S, Karabelis A, Beer M and Kosmidis P (1992) A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer. Ann Oncol 3: 127–130
Paesmans M and Sculier JP (1998) Facteurs pronostiques des cancers bronchopulmonaries. In: Cancers Bronchopulmonaires, Milleron B, Depierre A (eds). pp. 239–247, Vélizy-Villacoublay: Arnette
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P and Klastersky J for the European Lung Cancer Working Party (1995) Prognostic factors for survival in advanced non small cell lung cancer; uni and multivariate analyses including recpam analysis in 1052 patients. J Clin Oncol 13: 1221–1230
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P and Klastersky J for the European Lung Cancer Working Party (1997) Response to chemotherapy has a discriminant value on the distribution of further survival for patients with advanced non small cell lung cancer: a ten years experience of the European Lung Cancer Working Party. Eur J Cancer 33: 2326–2332
Robert F, Omura GA, Birch R, Krauss S and Oldham R (1984) Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: a Southeastern Cancer Study Group trial. J Clin Oncol 2: 391–395
Rosso R, Salvati F, Ardizzoni A, Curcio CG, Rubagotti A, Belli M, Castagneto B, Fusco V, Sassi M, Ferrara G, Pizza A, Pedicini T, Soresi E, Scoditti S, Cioffi R, Folco U, Monaco M, Merlano M, Rimoldi R, Tonachella R, Cruciani A, Colantuoni G, Rinaldi M, Portalone L, Bruzzi P and Santi L (1990) Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Cancer 66: 130–134
Sculier JP, Berghmans T, Castaigne C, Lalami Y, Luce S, Sotiriou C, Vermylen P and Paesmans M 1999a) Best supportive care or chemotherapy for stage IV non small cell lung cancer. In: Progress and Perspectives in Lung Cancer, Van Houtte P, Klastersky J, Rocmans P (eds). pp. 199–207, Berlin: Springer Verlag
Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Dabouis G, Efremidis A, Ries F, Berchier MC, Sergysels R, Mommen P and Paesmans M for the European Lung Cancer Working Party 1994a) Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 12: 353–359
Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, Berchier MC, Van Cutsem O, Küstner U, Kroll F, Sergysels R, Mommen P and Klastersky J for the European Lung Cancer Working Party (1996) A randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small cell lung cancer. J Clin Oncol 14: 2337–2344
Sculier JP, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Schmerber J, Giner V, Berchier MC, Sergyselq R, Mommen P and Klastersky J for the European Lung Cancer Working Party 1994b) Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non small cell lung cancer. Eur J Cancer 30A: 1342–1347
Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Efremidis A, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V and Klastersky J for the European Lung Cancer Working Party (1998) Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. J Clin Oncol 16: 1388–1396
Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Koumakis G, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V and Klastersky J for the European Lung Cancer Working Party 1999b) A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic–pharmacodynamic analysis in patients with advanced non-small cell lung cancer. Eur J Cancer 35: 1314–1319
Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F and Saijo N (1991) A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer 27: 571–575
Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tominaga K, Sakurai M, Suga J, Miyoaka H, Sano T, Keicho N, Takahashi H, Ishihara J, Tamura T, Hoshi A and Jett JR (1986) Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 77: 782–789
Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Comier Y, Ganz A, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL and Bernard JP (1993) Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 342: 19–21
Thongprasert S, Sanguanmitra P, Juthapan W and Clinch J (1999) Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24: 17–24
Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CA, Taylor SA and Livingston RB (1991) A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 9: 1157–1162
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR and Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459–2465
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sculier, JP., Lafitte, JJ., Paesmans, M. et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 83, 1128–1135 (2000). https://doi.org/10.1054/bjoc.2000.1413
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1413